Biotech funding rebound set to boost CDMO demand by early 2027

Analysts note that demand for pharma services has historically lagged behind biotech funding, but a recent surge in venture capital is expected to drive activity for contract development and manufacturing organizations later this year or early next.

PitchBook data shows quarterly biopharma venture capital deployment topped $10 billion, highlighted by Isomorphic Labs' $2.1 billion Series B and large exits including multibillion‑dollar takeovers by Eli Lilly and Gilead.

Based on past patterns, PitchBook forecasts CDMOs will see stronger demand over the next two to four quarters, indicating growth for the CDMO sector.